

Summary and Q&A

Eric Prystowsky, MD, FACC

Consulting Professor
Department of Medicine
Duke University School of Medicine
Durham, North Carolina

Director, Clinical Electrophysiology Lab
St. Vincent Hospital
Indianapolis, Indiana

Please see accompanying full prescribing information, including **boxed WARNING**.

MULTAQ: Summary

- MULTAQ is the only antiarrhythmic agent for AF shown to significantly reduce CV hospitalizations based on ATHENA*
- MULTAQ is indicated in patients with paroxysmal or persistent AF/AFL with CV risk factors* who are in sinus rhythm, or will be cardioverted
- MULTAQ is contraindicated in Class IV HF or Class II-III HF with recent decompensation
- Features of MULTAQ
 - Outpatient initiation
 - Dosing regimen
 - No loading dose; 400 mg BID with food
 - No clinically significant INR increases with warfarin
 - Low lipophilicity and half life of 13-19 hours

*Age \geq 70, Hypertension, diabetes mellitus, stroke/TIA, LA \geq 50 mm, LV EF <40%

MULTAQ [package insert]. Bridgewater, NJ; sanofi-aventis US LLC: 2009.

Please see accompanying full prescribing information, including **boxed WARNING**.

DR. PRYSTOWSKY:

Okay. So, MULTAQ is the only antiarrhythmic agent for A-fib that's been shown to significantly reduce cardiovascular hospitalizations, and that's based on the ATHENA Trial that Dr. Kowey so nicely went through with you.

MULTAQ is indicated in patients with paroxysmal or persistent A-fib or flutter, with cardiovascular risk factors that Dr. Kowey showed you, who are in sinus rhythm, or in whom you wish to get them into sinus rhythm. It's contraindicated, very important to remember, class four heart failure, or, class two or three heart failure when there's been a recent decompensation.

Features of MULTAQ that have been discussed here that I think you need to know about, and very importantly, is outpatient initiation. There's one dosing regimen, of 400 milligrams twice a day, with food, very important, do it with food. There has, to this point, shown no clinically significant INR increases with warfarin, which is also important. You do not have to worry about manipulating that. And the low lipophilicity and half life of 13 to 19 hours makes it a shorter onset and shorter offset.

If you have questions about MULTAQ®

- Contact your sanofi-aventis sales professional
- Visit www.MULTAQ.com

Please see accompanying full prescribing information, including boxed WARNING.

VOICE OVER SCRIPT

If you have additional questions about MULTAQ, please contact your sanofi-aventis sales professional, or refer to the MULTAQ.com website.